GSK

Business Context and Reporting Period

This Form 6-K filing, dated December 19, 2018, reports a material corporate transaction for GlaxoSmithKline plc (GSK). GSK has entered into an agreement with Pfizer Inc. to combine their respective consumer health businesses into a new world-leading Joint Venture (JV). The transaction is designed to accelerate GSK's strategy, create shareholder value, and lay the foundation for the future separation of GSK into two distinct UK-based global companies: one focused on Pharmaceuticals/Vaccines and the other on Consumer Healthcare.

Key Financial Metrics and Transaction Terms

The filing provides specific financial data regarding the businesses being contributed to the Joint Venture based on 2017 figures, as well as projected metrics for the combined entity.

• Combined Sales: Approximately £9.8 billion ($12.7 billion) for the combined JV based on 2017 sales.
• Equity Structure: GSK will hold a 68% controlling interest; Pfizer will hold a 32% interest.
• Cost Synergies: The JV expects to generate total annual cost savings of £0.5 billion by 2022. This includes expected total cash costs of £0.9 billion and non-cash charges of £0.3 billion.
• Target Margins: The JV targets an Adjusted operating margin in the "mid-to-high 20's" by 2022.
• Dividend Policy: GSK confirms an expectation to pay 80 pence per share in dividends for both 2018 and 2019.
• Break Fee: GSK agreed to pay a break fee of US$900 million under specific conditions (e.g., shareholder rejection or failure to close by set dates).

2017 Financials of Contributed Businesses

Note: GSK figures are IFRS; Pfizer figures are US GAAP. No reconciliation between standards was performed for the combined sales figure.

Material Changes and Strategic Outlook

The transaction represents a transformational change to the scale of GSK's Consumer Healthcare business. Key strategic elements include:

• Market Position: The JV will be the global leader in OTC products with a 7.3% market share, ahead of the nearest competitor at 4.1%. It will hold number 1 or 2 market share positions in all key geographies.
• Accretion: GSK expects the transaction to be accretive to Adjusted earnings and free cash flow in the first full year after closing, and accretive to Total earnings in the second full year.
• Future Separation: Within 3 years of closing, GSK intends to separate the JV via a demerger and listing on the UK equity market. The new Consumer Healthcare company is expected to support higher leverage levels, allowing the remaining Pharmaceuticals/Vaccines company to reduce its leverage.
• Divestments: Planned divestments targeting around £1 billion in net proceeds are expected to cover the cash costs of integration.

Management Commentary and Risks

CEO Emma Walmsley stated the transaction accelerates GSK's priorities to improve long-term competitive performance and strengthen the R&D pipeline. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to economic conditions, regulatory changes, and integration risks.

Conditions to Closing: The transaction is subject to GSK shareholder approval and anti-trust authority approvals. Closing is expected in the second half of 2019.

Investor Verification Checklist

• Verify the final shareholder vote outcome and the receipt of all necessary anti-trust approvals.
• Monitor the actual closing date, currently targeted for the second half of 2019.
• Review the formal circular to be sent to shareholders in Q1 2019 for detailed terms.
• Track the progress of the planned divestments (e.g., Horlicks to Unilever) to ensure they cover integration cash costs.
• Assess the timeline and mechanics of the intended separation and listing of the Consumer Healthcare business within 3 years of closing.